PRINCETON, N.J., Oct. 4, 2022
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a
leader in the treatment of life-threatening conditions in the
intensive care unit and cardiac surgery using blood purification,
announces that Dr. Phillip Chan,
Chief Executive Officer, will present at the Dawson James
Securities 2022 Small Cap Growth Conference on Wednesday, October 12th, 2022. Company
management will also meet with investors in 1x1 meetings throughout
the conference. To schedule a meeting with management, please
contact your Dawson James
representative.
Dawson James Securities 2022 Small Cap Growth
Conference
When: Wednesday, October 12, 2022 from 2:30-2:55PM EDT
Webcast: Dawson James Securities Conference Webcast
Link
A live webcast of the presentation will be available at the
above webcast link. An archived recording of CytoSorbents'
presentation at the conference will be available under the Investor
Relations portion of the Company's website at Events &
Presentations - CytoSorbents, and will be available for 90
days.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in the intensive care unit and in
cardiac surgery through blood purification. Its lead product,
CytoSorb®, is approved in the European Union and distributed in
more than 70 countries worldwide. It is an extracorporeal cytokine
adsorber that reduces "cytokine storm" or "cytokine release
syndrome" in common critical illnesses that can lead to massive
inflammation, organ failure and patient death. In these
diseases, the risk of death can be extremely high, and there are
few, if any, effective treatments. CytoSorb is also used
during and after cardiothoracic surgery to remove inflammatory
mediators that can lead to postoperative complications, including
multiple organ failure. As of June 30,
2022, more than 179,000 CytoSorb devices have been used
cumulatively. CytoSorb was originally launched in the
European Union under CE mark as the first cytokine adsorber.
Additional CE mark extensions were granted for bilirubin and
myoglobin removal in clinical conditions such as liver disease and
trauma, respectively, and for ticagrelor and
rivaroxaban removal in cardiothoracic surgery
procedures. CytoSorb has also received FDA Emergency Use
Authorization in the United
States for use in adult critically ill COVID-19 patients
with impending or confirmed respiratory failure. The
DrugSorb™-ATR antithrombotic removal system, based on the same
polymer technology as CytoSorb, also received two FDA Breakthrough
Device Designations, one for the removal of ticagrelor and
another for the removal of the direct oral anticoagulants (DOAC)
apixaban and rivaroxaban in a cardiopulmonary bypass circuit
during urgent cardiothoracic procedures. The company has
initiated two FDA-approved pivotal studies to support FDA marketing
approval of DrugSorb-ATR in the United States. The first is
the randomized, controlled STAR-T (Safe and Timely Antithrombotic
Removal-Ticagrelor) study of 120 patients at 30 centers to evaluate
whether intraoperative use of DrugSorb-ATR can reduce the
perioperative risk of bleeding in patients receiving ticagrelor and
undergoing cardiothoracic surgery. The second study is the
STAR‑D (Safe and Timely Antithrombotic Removal-Direct Oral
Anticoagulants) randomized, controlled trial of 120 patients at 30
centers evaluating the intraoperative use of DrugSorb-ATR to reduce
perioperative bleeding risk in patients undergoing cardiothoracic
surgery and taking direct oral anticoagulants, including apixaban
and rivaroxaban.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other body fluids through pore
entrapment and surface adsorption. The company's technologies
have received more than $41.5 million
in non-dilutive grants, contracts and other non-dilutive funding
from DARPA, the U.S. Department of Health and Human Services (HHS),
the National Institutes of Health (NIH), the National Heart, Lung,
and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force,
U.S. Special Operations Command (SOCOM), Air Force Material Command
(USAF/AFMC) and others. The company has numerous marketed and
in-development products based on this unique blood purification
technology protected by numerous issued U.S. and international
patents and registered trademarks, as well as several pending
patent applications, including ECOS-300CY®, CytoSorb-XL™,
HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™,
DrugSorb™, DrugSorb™-ATR, ContrastSorb and others. For more
information, please visit the company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us on
Facebook and Twitter.
Forward-looking statements
This press release contains forward-looking statements that fall
within the safe harbor of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not
limited to, statements regarding our plans, objectives, future
goals and prospects for our business, expectations regarding the
future impact of COVID-19 or the ongoing conflict between
Russia and Ukraine, representations and assertions, and
are not historical facts and are generally identified by the use of
words such as "may," "should," "could," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential,"
"continue" and similar terms, although some forward-looking
statements are worded differently. You should be aware that the
forward-looking statements in this press release reflect
management's current beliefs and expectations, but that our actual
results, events and performance may differ materially from those in
the forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, the
risks disclosed in our Annual Report on Form 10-K filed with the
SEC on March 10, 2022, our Quarterly
Reports on Form 10-Q and the press releases and other
communications to stockholders that we issue from time to time
seeking to inform interested parties of the risks and factors that
may affect our business. We caution you not to place undue reliance
on such forward-looking statements. We are under no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as required by federal securities laws.
Please Click to Follow Us on Facebook and Twitter
CytoSorbents Contact:
Kathleen Bloch
(732) 398-5429
kbloch@cytosorbents.com
Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-dawson-james-securities-2022-small-cap-growth-conference-301639869.html
SOURCE CytoSorbents Corporation